Kwangdong Phar (009290) - Total Liabilities

Latest as of March 2026: ₩606.09 Billion KRW ≈ $410.74 Million USD

Based on the latest financial reports, Kwangdong Phar (009290) has total liabilities worth ₩606.09 Billion KRW (≈ $410.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 009290 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Kwangdong Phar - Total Liabilities Trend (2011–2025)

This chart illustrates how Kwangdong Phar's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 009290 total assets.

Kwangdong Phar Competitors by Total Liabilities

The table below lists competitors of Kwangdong Phar ranked by their total liabilities.

Company Country Total Liabilities
Shin Yang Shipping Corporation Bhd
KLSE:5173
Malaysia RM481.64 Million
Rhom Bho Property Public Company Limited
BK:TITLE
Thailand ฿12.09 Billion
Hudson Technologies Inc
NASDAQ:HDSN
USA $78.80 Million
Utah Medical Products Inc
NASDAQ:UTMD
USA $4.01 Million
ST George Mining Ltd
AU:SGQ
Australia AU$3.54 Million
Kaltura Inc
NASDAQ:KLTR
USA $167.13 Million
BAJEL PROJECTS LTD
NSE:BAJEL
India Rs-7.48 Billion
Shenzhen Dvision Video Communica
SHE:300167
China CN¥492.69 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Kwangdong Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Kwangdong Phar to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.94 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Kwangdong Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Kwangdong Phar (2011–2025)

The table below shows the annual total liabilities of Kwangdong Phar from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩608.53 Billion
≈ $412.39 Million
+10.24%
2024-12-31 ₩552.01 Billion
≈ $374.09 Million
+12.65%
2023-12-31 ₩490.02 Billion
≈ $332.08 Million
+27.28%
2022-12-31 ₩384.98 Billion
≈ $260.89 Million
+7.96%
2021-12-31 ₩356.60 Billion
≈ $241.66 Million
+8.57%
2020-12-31 ₩328.46 Billion
≈ $222.59 Million
-4.88%
2019-12-31 ₩345.32 Billion
≈ $234.02 Million
+14.64%
2018-12-31 ₩301.22 Billion
≈ $204.13 Million
-1.69%
2017-12-31 ₩306.40 Billion
≈ $207.64 Million
+9.39%
2016-12-31 ₩280.10 Billion
≈ $189.82 Million
-2.08%
2015-12-31 ₩286.06 Billion
≈ $193.86 Million
+123.25%
2014-12-31 ₩128.13 Billion
≈ $86.83 Million
-4.98%
2013-12-31 ₩134.85 Billion
≈ $91.39 Million
+10.39%
2012-12-31 ₩122.16 Billion
≈ $82.79 Million
+69.28%
2011-12-31 ₩72.16 Billion
≈ $48.91 Million
--

About Kwangdong Phar

KO:009290 Korea Packaged Foods
Market Cap
$216.74 Million
₩319.82 Billion KRW
Market Cap Rank
#16338 Global
#595 in Korea
Share Price
₩6440.00
Change (1 day)
+1.42%
52-Week Range
₩5270.00 - ₩11080.00
All Time High
₩11611.32
About

Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more